Testosterone, Anabolic Steroids, and 280E: The Schedule III Tax Answer

Hormone and testosterone replacement clinics ask us a version of the same question that peptide operators ask, but with an extra layer of worry: "Testosterone is a controlled substance. We keep DEA records. Does that put us in 280E territory like a dispensary?" The answer is no, and the reason is precise. Section 280E disallows deductions for a trade or business trafficking in controlled substances "within the meaning of schedule I and II of the Controlled Substances Act." Testosterone and the anabolic steroids are controlled substances - but they are Schedule III. Congress drew the line at Schedule II, and a Schedule III substance does not cross it.

This is the same statutory clause the IRS has used to deny ordinary deductions to cannabis operators - an application we have publicly challenged for years, because we maintain cannabis never truly met the Schedule I criteria in the first place. For a hormone clinic, the clause cuts cleanly in the operator's favor. The substances are scheduled, the recordkeeping is real, the DEA registration on the prescriber's wall is real, and none of it triggers 280E, because none of it involves a Schedule I or Schedule II substance.

How Steroids Ended Up on Schedule III

Anabolic steroids were not originally scheduled at all. The Anabolic Steroid Control Act of 1990 placed them on Schedule III of the federal Controlled Substances Act, alongside ketamine and buprenorphine. Congress expanded the list in 2004, and the Designer Anabolic Steroid Control Act of 2014 broadened it again to capture designer compounds marketed as supplements. Testosterone itself - the molecule at the center of every TRT protocol - is Schedule III under the same framework.

Schedule III status carries genuine regulatory weight. Prescribers need DEA registration. Dispensing and administration records must be kept. Refill limits apply. State controlled substance registrations layer on top. But for tax purposes, the schedule number is the whole analysis. Relying on the statutory language, 280E requires a substance within the meaning of Schedule I or II. Schedule III is outside the statute. The disallowance never attaches.

Human growth hormone occupies its own odd lane and deserves a sentence of precision: HGH is not a scheduled substance at all, but federal law separately criminalizes its distribution for any use other than an FDA-approved indication pursuant to a valid prescription. That is a compliance issue for the clinical side of the practice, not a 280E issue for the tax return.

The Compliance Layer That Actually Matters

Because the tax answer is clean, the planning attention belongs on the regulatory layer, where hormone clinics carry obligations that peptide-only operators do not.

DEA and state registrations. Every prescriber writing testosterone needs a current DEA registration, and most states require a separate state controlled substance registration on top of the medical license. Lapses here are not tax problems, but they are the kind of finding that turns a routine state board inquiry into something worse.

Telehealth prescribing. The Ryan Haight Act generally requires an in-person evaluation before a controlled substance is prescribed via telemedicine. The DEA has extended its pandemic-era telemedicine flexibilities repeatedly - the current extension runs through the end of 2026 - while the permanent special registration rulemaking remains unfinished. A clinic built on remote TRT consults needs current counsel on where the rule stands, and a plan for what the model looks like if the final rule tightens the in-person requirement. This is the single most common structural risk we see in telehealth hormone models.

In-office dispensing versus pharmacy fulfillment. Clinics that stock and administer testosterone in-office hold inventory of a Schedule III substance, with storage, security, and recordkeeping obligations. Clinics that route everything through a 503A compounding pharmacy or a retail pharmacy push that burden downstream. The choice shapes both the compliance footprint and the COGS profile of the books.

Entity Structure: The Same CPOM Discipline as Any Clinic

The structural analysis for a hormone clinic tracks what we laid out in our peptide clinic article. In a Corporate Practice of Medicine state, the clinical entity generally must satisfy the state's professional ownership rules, with a management services organization holding the brand, lease, equipment, and non-clinical staff under an arm's length management services agreement. In a non-CPOM state, a single PLLC or LLC with an S-corp election once income justifies it is typically sufficient. Most hormone clinics need a medical director arrangement consistent with state supervision rules, and the reasonable compensation analysis for the owner-employee should be documented annually.

Clinics in our home state should treat that conventional playbook with extra care. Oregon enacted Senate Bill 951 in 2025, codifying and strengthening its corporate practice of medicine doctrine and placing significant new restrictions on how management services organizations may own, influence, or control professional medical entities - including limits on dual ownership and on the contractual levers MSOs have traditionally relied on. New arrangements generally must comply beginning in 2026, and existing structures generally have until 2029 to come into compliance. An Oregon hormone clinic considering an MSO arrangement, or already operating one, should have the structure reviewed against SB 951 with healthcare counsel before relying on it. We flag this in every Oregon clinic engagement.

Deductions, and the 199A Wrinkle Clinics Should Expect

With 280E out of the analysis, IRC 162 applies in full: rent, payroll, marketing, lab fees, software, insurance, professional fees, all deductible as ordinary and necessary business expenses. Inventory accounting follows standard IRC 471 rules, and operators under the section 471(c) small business threshold (currently approximately $29 million in average annual gross receipts) have flexibility in method.

The wrinkle is IRC 199A. The 20% qualified business income deduction phases out for specified service trades or businesses above the income thresholds, and the performance of services in the field of health is a specified service. A physician-owned clinical entity generating high income should expect the SSTB limitation to bite. This is one of the quiet arguments for a properly structured MSO: the management company's income is not the performance of health services, and its 199A posture is analyzed separately from the clinical entity's. In Oregon, the SB 951 restrictions described above shape whether and how an MSO split is available at all - the tax analysis cannot run ahead of the structural one. We model this split for every clinic client rather than assuming the deduction is either fully available or fully lost.

Where Hormone Clinics Actually Get Hurt

The assessments we see in this space do not come from 280E. They come from the ordinary failure points of a fast-growing clinical business. Self-employment tax overpayment where an S-corp election was never made. Reasonable compensation set by guesswork instead of documentation. Sales tax ignored on the supplement and retail product line sold alongside clinical services - the services may be exempt while the products are taxable, and the distinction has to be tracked at the point of sale. Multi-state exposure when a telehealth model quietly builds patient bases, and sometimes employees, across state lines. Each of these is preventable with structure set up before growth, and expensive to fix after.

What Calyx Does for Hormone and TRT Clinics

Entity formation aligned to Corporate Practice of Medicine doctrine, including the MSO and PC split where the state requires it. S-corp elections, payroll setup, and annual reasonable compensation documentation. Monthly accounting that separates clinical service revenue from taxable retail product revenue and allocates COGS correctly between them. Multi-state sales tax registration and remittance where the product line creates nexus. Federal and state return preparation, and audit representation if a return we prepared draws a question.

The Position, Restated

Testosterone and anabolic steroids are Schedule III controlled substances. Section 280E reaches only substances within the meaning of Schedule I and II. A TRT or hormone clinic is therefore entitled to ordinary tax treatment: full IRC 162 deductibility, standard inventory accounting, and IRC 199A eligibility subject to the SSTB rules that apply to any health services business. The controlled substance compliance obligations are real and belong on the clinical side of the house. The tax return is not where that burden lands.

If your clinic's current preparer has hedged on this, or treated DEA paperwork as a reason to limit deductions, the return is wrong and it is correctable. Contact us through the Calyx CPA site to start a conversation.

This article is intended for informational purposes only and does not constitute legal, tax, or medical advice.